November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

Comparing Healthcare Sector ETFs: VanEck Pharma vs. iShares Biotech

🏛️ Economy 2 min read 👁 2

Investors evaluating healthcare exchange-traded funds must weigh the steady, dividend-paying focus of pharmaceutical giants against the broader, more volatile nature of biotechnology innovators.

Comparing Healthcare Sector ETFs: VanEck Pharma vs. iShares Biotech🏛️Economy

Photo: Motley Fool

Key points

  • VanEck Pharmaceutical ETF features a concentrated basket of 26 holdings with a 1.8% dividend yield and a 0.36% expense ratio.
  • iShares Biotechnology ETF provides broader exposure across 243 holdings with a 0.2% dividend yield and a 0.44% expense ratio.
  • Pharmaceutical funds offer exposure to mature drugmakers involved in industry acquisitions, whereas biotech portfolios lean toward higher price volatility tied to research developments.

When selecting a healthcare-focused exchange-traded fund, market participants face a distinct choice between the concentrated, income-generating portfolio of the VanEck Pharmaceutical ETF (PPH) and the expansive, higher-volatility holdings of the iShares Biotechnology ETF (IBB). Established in 2011, the VanEck fund holds 26 assets with a heavy emphasis on major drug manufacturers. Its top positions include Eli Lilly at 23.24%, Merck & Co at 12.56%, and Novo Nordisk at 5.42%. Over the trailing 12 months, the fund distributed $2.14 per share, translating to a 1.8% yield based on its share price of roughly $119.21. Furthermore, it carries an expense ratio of 0.36%.

Conversely, the iShares Biotechnology ETF launched in 2001 and offers significantly broader diversification with 243 holdings, dedicating 87% to biotechnology and 10% to life sciences. Its major weightings feature Gilead Sciences at 8.94%, Amgen at 8.31%, and Vertex Pharmaceuticals at 7.87%. The fund paid $0.34 per share over the trailing 12 months, resulting in a 0.2% yield on its share price of approximately $213.79, while maintaining a slightly higher expense ratio of 0.44%.

The structural differences between the two funds reflect distinct risk tolerances and investment strategies. While the pharmaceutical fund provides exposure to mature companies engaging in mergers and acquisitions amid expiring patents, the biotech fund captures smaller developers whose valuations can swing dramatically on clinical trial results or buyout news.

Source Motley Fool — fool.com/coverage/etfs/2026/11/15/which-healthcare-etf-is-the-bette… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.